Category: Today’s Highlights
Gilead's Positive News Exceeds By-Far Its Negative News. Who Said Gilead Needs Acquisitions to Maintain Its Growth?
Results from trials were negative in two phase 2 studies for Gilead (GILD) experimental drug GS-4997 ( selonsertib ) intended to treat pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). But the same drug selonsertib showed it might hit...
Read More
October 21, 2016
0
Incyte and Lilly: Conquering Rheumatoid Arthritis
At the Annual European Congress of Rheumatology (EULAR 2016) in London, Eli Lilly and Company (LLY) and Incyte (INCY) presented data from RA-BEYOND study, demonstrating that their drug baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in...
Read More
October 18, 2016
0
Ophthotech Bad News Adds to Regeneron Good News
Today we have good news and bad news. The good news is coming from Regeneron (REGN) through two sources: The first is the European Medicines Agency accepting Regeneron’s and Sanofi’s (SNY) Filing for the approval of Dupixent (dupilumab) for moderate to...
Read More
December 12, 2016
0
Bellicum Is Outperforming and So Should Be Its Stock
Bellicum Pharmaceuticals (BLCM) announced results from the BP-004 multicenter clinical trial for children with Primary Immune Deficiencies (PIDs) and hemoglobinopathies. The candidates received an add-back of Bellicum’s BPX-501 modified T cells following a haploidentical, T cell-depleted hematopoietic stem cell transplant...
Read More
December 5, 2016
0
It Is All About Array Biopharma
Prohost Biotech On ARRAY PHARMACEUTICALS Under the title “ Halozyme has Good News and Array Too”, we wrote the following about Array On Nov. 5, 2015. Array’s (ARRY) internal, broad based drug discovery and research technological capabilities is behind the creation...
Read More
November 22, 2016
0
About the News from Incyte and Vertex
Incyte: A Good Company Facing Irrelevant Investors’ Reaction Incyte decided to stop an early ongoing trial of a combination treatment ruxolitinib (Incyte) plus regorafenib (Bayer) for colon cancer after observing the combination wasn’t working. Both drugs are approved for different...
Read More
January 28, 2016
0
Halozyme: Reading the News While Keeping Our Focus on the Promises
Halozyme Therapeutics (HALO) seems to have closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is said to be secured by future royalties of ENHANZE™ products, received...
Read More
January 27, 2016
0
Theravance Biopharma: Launching Vibativ in Canada for MRSA
Theravance Biopharma (TBPH) announced the commercial launch of VIBATIV® (telavancin) in Canada. VIBATIV is a once-daily antibiotic with a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat methicillin-resistant Staphylococcus aureus (MRSA). The drug is approved in Canada for adult...
Read More
January 26, 2016
0
Revolutionary Approaches Towards Managing Chronic and Deadly Diseases
The Market is Surely Ignoring the Historical Summit Biotech achievements are standing on Right Now The latest biotech sector’s breakthroughs we presented was the novel powerful gene editing techniques CRISPR/cas9 an d TALEN. Our article in the Prohost...
Read More
January 22, 2016
0
OIL: A Blessing or a Curse? It Depends on What Some Want it to Be
Escaping the slaughter, or taking advantage of it, or accumulating the stocks we love, or turning from positive to negative investors are all choices on the table. The problem is that the prophets stop prophesizing at times when prophesies are...
Read More
January 20, 2016
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)